SCHEMBL6407413

SCHEMBL6407413

CC(=O)N(c1ccc(Oc2ccc3ccccc3c2)cc1)c1ccccc1C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
CASP3 P42574 2/20 0.46
NSD2 O96028 1/20 0.46
CASP7 P55210 1/20 0.46
CASP9 P55211 1/20 0.46
CASP6 P55212 1/20 0.46
CASP8 Q14790 1/20 0.46
PTPN1 P18031 6/20 0.46
TSHR P16473 1/20 0.42
KEAP1 Q14145 1/20 0.41
NFE2L2 Q16236 1/20 0.41
PARP1 P09874 1/20 0.41
PARG Q86W56 1/20 0.41
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
POLB P06746 2/20 0.40
SENP8 Q96LD8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6401909 0.92 PTPN1 (0.51) MEN1KMT2AL3MBTL1CASP3NSD2
SCHEMBL28605602 0.87 PTPN1 (0.51) MEN1KMT2ACASP3NSD2CASP7
SCHEMBL8044308 0.86 PTPN1 (0.45) MEN1KMT2AL3MBTL1CASP3NSD2
SCHEMBL8027747 0.82 ALDH1A1 (0.47) MEN1KMT2APTPN1TSHRALDH1A1
SCHEMBL8038284 0.82 ALDH1A1 (0.49) PTPN1ALDH1A1
SCHEMBL6408806 0.81 ALOX5 (0.50) PTPN1ALDH1A1
SCHEMBL8041238 0.81 LTA4H (0.51) PTPN1TSHR
SCHEMBL6404636 0.80 KMT2A (0.44) MEN1KMT2AL3MBTL1CASP3PTPN1
SCHEMBL8041220 0.80 MTNR1A (0.41) PTPN1HPGDPOLB
SCHEMBL8034169 0.79 PTPN1 (0.50) MEN1KMT2APTPN1TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050027008-A1 Cancer remedy comprising anthranilic acid derivatives as active ingredient TEIJIN LIMITED 2005-02-03 US disclosed
US-20030220402-A1 Cancer remedy comprising anthranilic acid derivatives as active ingredients TEIJIN LIMITED (JP) 2003-11-27 US disclosed
EP-1256341-A1 CANCER REMEDY COMPRISING ANTHRANILIC ACID DERIVATIVE AS ACTIVE INGREDIENT TEIJIN LIMITED (JP) 2002-11-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220402-A1 Cancer remedy comprising anthranilic acid derivatives as active ingredients HCCS, BCOR, CBR1 MEN1 3155/4885KMT2A 553/4885L3MBTL1 2029/4885
US-20050027008-A1 Cancer remedy comprising anthranilic acid derivatives as active ingredient CA9, HCCS, CA7 MEN1 1552/4885KMT2A 799/4885L3MBTL1 1394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.